| Pharmaceutical Information |
| Drug Name |
Natalizumab |
| Drug ID |
BADD_D01537 |
| Description |
Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006. |
| Indications and Usage |
For treatment of multiple sclerosis. |
| Marketing Status |
Prescription |
| ATC Code |
L04AA23 |
| DrugBank ID |
DB00108
|
| KEGG ID |
D06886
|
| MeSH ID |
D000069442
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
64406-008 |
| Synonyms |
Natalizumab | Tysabri | Antegren |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
189261-10-7 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
